辛迪制药 SNDX
$9.54 +$0.17 (+1.81%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $9.70 +1.68%
开盘$9.59
昨收$9.37
当日区间$9.22 – $9.78
成交量4.17M
市值$858.87M
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例123.0%-0.48 个百分点，较上季度
持仓机构数301-1 ，较上季度
内部人近期交易26次买入 / 22次卖出净买入
空头持仓比例20.16% 占流通股回补天数 7.6 · 截至 15 Oct 2026
卖空成交量占比11.6%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$11.28M（3个净流入日，17个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有36.7%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从25.58%降至20.16%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +1,854,436 | 2.3% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,228,348 | 6.3% |
| Loomis, Sayles & Company L.P. | Mutual Fund | 2026/Q3 | +923,624 | 1.0% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q3 | +770,708 | 1.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +765,580 | 10.1% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +751,614 | 2.3% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +669,815 | 6.1% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +579,700 | 1.7% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +456,700 | 0.5% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +441,135 | 0.5% |
| Prosight Management, LP | Hedge Fund | 2026/Q3 | +430,000 | 1.3% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +427,078 | 2.9% |
| Trails Edge Capital Partners, LP | Hedge Fund | 2026/Q3 | +408,179 | 1.2% |
| Leap Investments LP | Mutual Fund | 2026/Q3 | +401,300 | 0.4% |
| Jupiter Fund Management Plc | Mutual Fund | 2026/Q3 | +366,568 | 0.4% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 7 Jul 2026 | Michael Metzger | Chief Executive Officer | Derivative Exercise and Sale | -32,375 | $24.24 | 63,160 |
| 11 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -31,235 | $18.14 | – |
| 11 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -53,750 | $18.14 | 60,885 |
| 10 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -11,765 | $18.00 | 60,885 |
| 31 May 2026 | Keith Goldan | CFO, Treasurer & Principal Accounting Officer | Open Market Disposition | -1,177 | $18.99 | 27,902 |
| 31 May 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -6,847 | $18.99 | 63,160 |
| 8 Feb 2026 | Keith Goldan | CFO, Treasurer & Principal Accounting Officer | Open Market Disposition | -3,410 | $21.03 | 29,079 |
| 8 Feb 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -17,159 | $21.03 | 70,007 |
| 5 Feb 2026 | Keith Goldan | CFO, Treasurer & Principal Accounting Officer | Open Market Disposition | -2,082 | $20.62 | 20,822 |
| 5 Feb 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -7,412 | $20.62 | 87,166 |
| 3 Feb 2026 | Keith Katkin | Independent Director | Other Acquisition | +24,000 | – | 49,000 |
| 3 Feb 2026 | Pierre Legault | Independent Director | Other Acquisition | +24,000 | – | 114,000 |
| 3 Feb 2026 | Keith Goldan | CFO, Treasurer & Principal Accounting Officer | Other Acquisition | +52,250 | – | 123,017 |
| 3 Feb 2026 | Keith Goldan | CFO, Treasurer & Principal Accounting Officer | Other Derivative Acquisition | +118,000 | $20.43 | 118,000 |
| 3 Feb 2026 | Dennis Podlesak | Independent Chairperson | Other Acquisition | +48,000 | – | 225,333 |
| 3 Feb 2026 | Michael Metzger | Chief Executive Officer | Other Acquisition | +217,600 | – | 421,683 |
| 3 Feb 2026 | Michael Metzger | Chief Executive Officer | Other Derivative Acquisition | +440,000 | $20.43 | 440,000 |
| 3 Feb 2026 | Jennifer Jarrett | Independent Director | Other Acquisition | +24,000 | – | 114,000 |
| 3 Feb 2026 | Aleksandra Rizo | Independent Director | Other Acquisition | +24,000 | – | 49,000 |
| 3 Feb 2026 | Martin Huber | Independent Director | Other Acquisition | +24,000 | – | 98,000 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 18,001,644 | 20.2% | 7.6 |
| 30 Sep 2026 | 18,234,880 | 20.4% | 8.5 |
| 15 Sep 2026 | 20,660,449 | 23.1% | 14.7 |
| 31 Aug 2026 | 21,681,907 | 24.3% | 19.7 |
| 14 Aug 2026 | 22,902,431 | 25.6% | 15.0 |
| 31 Jul 2026 | 22,665,216 | 25.6% | 18.6 |
暂无评论——快来第一个聊聊 SNDX。
登录后参与讨论。